Rationale Morphine is the prototypic mu opioid, producing its analgesic actions through traditional 7 transmembrane domain (7TM) G-protein-coupled receptors generated by the mu opioid receptor gene (Oprm1). However, the Oprm1 gene undergoes extensive alternative splicing to yield three structurally distinct sets of splice variants. In addition to the fulllength 7TM receptors, it produces a set of truncated variants comprised of only 6 transmembrane domains (6TM). Objectives This study explored the relative contributions of 7TM and 6TM variants in a range of morphine actions. Methods Groups of male and mixed-gender wild-type and exon 11 Oprm1 knockout mice were examined in a series of behavioral assays measuring analgesia, hyperalgesia, respiration, and reward in conditioned place preference assays. Results Loss of the 6TM variants in an exon 11 knockout (E11 KO) mouse did not affect morphine analgesia, reward, or respiratory depression. However, E11 KO mice lacking 6TM variants failed to show morphine-induced hyperalgesia, developed tolerance more slowly than wild-type mice, and did not display hyperlocomotion. Conclusions Together, our findings confirm the established role of 7TM mu receptor variants in morphine analgesia, reward, and respiratory depression, but reveal an unexpected obligatory role for 6TM variants in morphine-induced hyperalgesia and a modulatory role in morphine tolerance and dependence.
Introduction
Morphine acts through the mu opioid receptor, a G-proteincoupled receptor. Originally proposed based upon rigid structure-activity relationships (Beckett 1959; Portoghese 1966) , it was first demonstrated in binding assays in 1973 (Pert and Snyder 1973; Simon et al. 1973; Terenius 1973) and finally cloned in 1993 (Chen et al. 1993; Pasternak and Pan 2013; Thompson et al. 1993; Wang et al. 1993) . The importance of the cloned mu receptors in morphine analgesia was first demonstrated using an antisense approach (Rossi et al. 1994 ) and subsequently in a number of knockout mouse models (Becker et al. 2000; Charbogne et al. 2014; Corder et al. 2017; Kitanaka et al. 1998; Loh et al. 1998; Matthes et al. 1996; Schuller et al. 1999; Sora et al. 2001; Sora et al. 1997; Tian et al. 1997 ). While only a single mu opioid receptor gene, Oprm1, has been identified, the gene undergoes extensive splicing to generate dozens of splice variants (for review, Pasternak and Pan 2013) , revealing a complexity exceeding the original proposal of mu opioid receptor subtypes (Wolozin and Pasternak 1981) .
Oprm1 gene splice variants can be divided into three general groups based upon their structures (Supplemental Fig. 1 ). Most of the variants are traditional 7 transmembrane domain (7TM) G-protein-coupled receptors (GPCR) associated with the exon 1 promoter. A second set containing only a single Electronic supplementary material The online version of this article (doi:10.1007/s00213-017-4600-2) contains supplementary material, which is available to authorized users. transmembrane domain (1TM) potentiates morphine analgesia through a chaperone function that stabilizes the 7TM variants (Xu et al. 2013 ). The last group contains only 6 transmembrane (6TM) domains and is produced through the exon 11 promoter, which is distinct from the exon 1 promoter responsible for the 7TM and 1TM variants. All three groups undergo 3′ splicing to yield additional variants with alternative C-terminals. All sets of variants are expressed in the brain, but their regional distributions are quite varied, with their relative abundance at the messenger RNA (mRNA) levels differing widely from region to region Xu et al. 2014) .
Understanding the contributions of these individual splice variants in selected opioid actions has been difficult since many exons of the Oprm1 gene are shared among multiple splice variants. However, several knockout models have given some insights. One model had a disruption of exon 1 (E1 KO) (Schuller et al. 1999) . Although the traditional 7TM receptors and 1TM variants which contain exon 1 are eliminated in this model, the disruption did not eliminate all Oprm1 expression. The upstream exon 11 Oprm1 promoter was still active and continued to express 6TM variants, which do not contain exon 1. Morphine does not elicit analgesia in these animals at doses over 25-fold its ED 50 . A different knockout model targeting exon 11 (E11 KO) selectively eliminated 6TM variants while maintaining 7TM expression ). Morphine retained its analgesic activity in these E11 KO animals.
A number of other models have been generated, all of which lack 7TM variants and show no morphine analgesia (Charbogne et al. 2014; Corder et al. 2017; Kitanaka et al. 1998; Loh et al. 1998; Matthes et al. 1996; Schuller et al. 1999; Sora et al. 2001; Sora et al. 1997; Tian et al. 1997) . Several target either exon 2 or exons 2 and 3, eliminating both 6TM and 7TM variants. While these models can implicate the Oprm1 gene in a phenotype, they cannot distinguish between 7TM and 6TM actions. While additional models targeted exon 1 (Kitanaka et al. 1998; Sora et al. 1997; Tian et al. 1997) , the extent of their disruption of Oprm1 expression is not clear since 6TM expression was not examined. While loss of exon 1 will eliminate the 7TM and 1TM variants, the gene disruption may also impair its overall expression, including 6TM variants.
Morphine produces hyperalgesia that can become manifest after its analgesic actions wane (Elhabazi et al. 2014; Roeckel et al. 2016) . Initially, it was suggested that this might be associated with opioid receptor-mediated excitatory mechanisms (Crain and Shen 1990) acting through the μ 3 receptor (Stefano et al. 1995) , a truncated 6TM mu receptor variant (Cadet et al. 2003) , and more recently through another 6TM receptor, MOR-1K (Gris et al. 2010; Oladosu et al. 2015a) . A recent conditional exon 2 and 3 KO mouse revealed that hyperalgesia was mediated through mu opioid receptors on peripheral sensory neurons, although the knockout model, which targeted exons 2 and 3, could not distinguish between a 7TM or a 6TM mechanism (Corder et al. 2017 ). In the current study, we assessed the contributions of 6TM variants in a range of morphine actions in mice, including hyperalgesia, using a selective 6TM KO mouse model.
Methods
Mice C57/Bl6/J wild-type (C57; WT) (Jackson Laboratories) and exon 11 KO (E11 KO) ) mice were bred in our laboratory. E11 KO animals were derived as previously described ) and backcrossed more than ten generations on a C57/Bl6/J background. Since no obvious sex differences were noted, both male and female mice were included. WT and E11 KO were matched for age and sex. All mice were maintained on a 12-h light/dark cycle with food and water available ad libitum and housed in groups of five until testing. All animal studies were approved by the Institutional Animal Care and Use Committee of Memorial Sloan Kettering Cancer Center and performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals in an AAALAC-accredited facility.
Drugs
Morphine sulfate and naloxone were obtained from the Research Technology Branch of the National Institute on Drug Abuse (Rockville, MD). Naloxonazine (Hahn et al. 1982) and IBNtxA (3-iodobenzoyl-6β-naltrexamine) (Majumdar et al. 2011) were synthesized in our laboratory as previously described and structures validated.
Analgesia and hyperalgesia
Analgesia was assessed with the radiant heat tail flick assay using a Ugo Basile radiant heat tail flick machine (Varese, Italy) with baseline values between 2 and 3 s and a maximum latency of 10 s (D'Amour and Smith 1941; Hahn et al. 1982; Ling et al. 1985; Rossi et al. 1997) . Data were analyzed both as percent maximal possible effect (%MPE) and quantally, defined as a doubling or greater of baseline latency. %MPE was calculated with the formula [(response − baseline) / (10 − baseline)] × 100. Both methods of analysis yielded similar results. Tail flick analgesia was tested at peak effect at 30 min after morphine administration. ED 50 values were calculated by nonlinear regression analysis (GraphPad Prism, Carlsbad, CA).
Hyperalgesia was assessed using a tail immersion assay as previously described (Elhabazi et al. 2014 ). Mice were acclimated by handling them for 2-3 days prior to testing. At least 2 days prior to drug administration, baseline tail flick latencies were obtained using a tail immersion assay (Neslab, GP-100 Water Bath, 47°C). Baselines are reported as the mean of three tail flick latencies. Then, mice were administered saline or equianalgesic doses of morphine (10 mg/kg, s.c.) or IBNtxA (1.6 mg/kg, s.c.) and tested for analgesia after 30 min or for hyperalgesia 24 h after dosing. This was repeated daily.
Tolerance and dependence
Mice were injected daily with morphine (10 mg/kg, s.c.) and analgesia assessed on the indicated days using the radiant tail flick assay. On day 21, a dose-response curve was generated using cumulative dosing. The ED 50 values (95% confidence intervals) were calculated by nonlinear regression analysis (GraphPad Prism).
On day 21 of chronic daily morphine dosing (10 mg/kg, s.c.), mice were injected with naloxone (1 mg/kg, s.c.), and jumping was quantified for the next 15 min.
Locomotor activity
Open-field locomotor activity was obtained in a MedAssociates ENV-510 activity chamber (St Albans, VT) using MedAssociates Activity Monitor software. Mice were injected with saline or morphine (10 mg/kg, s.c.) and immediately placed in an open field box for 60 min. Total distance traveled and distance traveled in 2-min bins were compared using a one-way or repeated-measures ANOVA followed by Bonferroni multiple comparisons test (GraphPad Prism).
Respiratory depression
Respiratory rate was assessed in freely moving adult mice with the MouseOx pulse oximeter system (Starr Life Sciences) (Majumdar et al. 2011 ). Mice were shaved around the neck 24 h prior to testing. Mice were habituated to the device for at least 1 h prior to testing. A 5-s average breath rate was assessed at 5-min intervals. A baseline was obtained over a 25-min period before drug injection. Then, mice (n = 5-7 per group) received saline or morphine (1, 2.5, 5, or 10 mg/ kg, s.c.). Testing began 15 min post-injection and continued for 35 min. Data are reported as the percentage of baseline readings.
Conditioned place preference
A three-chamber conditioned place preference paradigm (Med Associates, Catalog #: ENV-3013) was used to assess morphine reward behavior in WT and E11 KO mice. First, mice underwent a 20-min pre-conditioning session during which they had free access to all chambers to determine their innate preference for a black chamber with a bar floor, a gray chamber with a solid floor, or a white chamber with a grid floor. Then, mice underwent conditioning for 4 days. On each conditioning day, mice received saline i.p. and were immediately placed in the chamber they showed innate preference for (either white or black) during pre-conditioning for 20 min. Four hours later, mice were injected with morphine (10 mg/ kg, i.p.) and immediately placed in the chamber they did not show preference for (either white or black) during the preconditioning phase. On the day following conditioning day 4, mice were tested for place preference. They were given free access to all chambers, and time spent in each chamber was quantified during a 20-min period. Preference was determined with a difference score of time spent in the drug paired chamber post-conditioning minus time spent in chamber pre-conditioning. Mice were considered as showing preference for morphine if their difference score was 100 s or greater.
Results

Analgesia
Prior studies from our laboratory found normal morphine responses in E11 KO mice in a mixed background ). In the current study, morphine analgesia was not statistically different in wild-type and E11 KO mice in the C57/ Bl6 background with ED 50 values of 3.5 and 3.6 mg/kg, s.c., respectively (Table 1) , consistent with earlier mixed background studies ).
The antagonists naloxazone and naloxonazine have proven helpful in pharmacologically distinguishing among various morphine mechanisms and led to the original suggestion of mu receptor subtypes (Pasternak et al. 1980a, b; Pasternak and Snyder 1975; Wolozin and Pasternak 1981) . When administered 24 h prior to testing, both antagonists decrease systemic and supraspinal (i.c.v.) morphine analgesia without blocking respiratory depression, inhibition of gastrointestinal transit, Groups of mice (n = 11-20) received morphine (s.c.) and were tested for analgesia with the tail flick assay. Cumulative dosing was used to generate analgesic dose-response curves, and with dose escalation, full maximal effects were obtained in all groups. The ED 50 s (95% confidence intervals) were calculated by nonlinear regression analysis (GraphPad Prism). Significance between groups was determined with an F-test. Data are reported with two experiments pooled to generate one doseresponse curve physical dependence, and a number of other morphine actions (Hahn et al. 1982; Heyman et al. 1988; Ling et al. 1984; Ling et al. 1985; Pasternak 2001; Pasternak and Pan 2013; Paul and Pasternak 1988; Spiegel et al. 1982 ). In the current studies, naloxonazine shifted the morphine ED 50 value in both wildtype and E11 KO mice by approximately threefold (Fig. 1a, b ; Table 1 ), indicating that the residual morphine analgesia in the E11 KO mice also was mediated through a naloxonazinesensitive target that was independent of 6TM variants. The ED 50 values for morphine in wild-type and E11 KO mice were not significantly different in the control or naloxonazine groups. Naloxonazine shifted the ED 50 of morphine by approximately threefold in both WT (F 1,82 = 56.67, p < 0.0001) and E11 KO (F 1,86 = 36.99, p < 0.0001) mice compared to controls.
Tolerance and dependence
The 6TM variants contribute to the development of morphine tolerance. When dosed daily (10 mg/kg, s.c.), morphine responses in wild-type mice gradually diminished over time (Fig. 1c) , with more than a sevenfold shift to the right of the ED 50 after 21 days ( Fig. 2) . By day 21, the responses in both WT and E11 KO mice returned to near baseline levels. However, dose-response curves on day 21 revealed that E11 KO mice were still significantly more sensitive to morphine (ED 50 13 mg/kg) than wild-type mice (ED 50 25.3 mg/kg) ( Table 1) . Following 21 days of morphine administration, the analgesic ED 50 of morphine was significantly lower in E11 KO than WT mice (F 1,94 = 18.27, p < 0.0001). Both morphine-treated groups were significantly different than their respective control groups (WT: F 1,73 = 35.1, p < 0.0001; E11 KO: F 1,65 = 25.94, p < 0.0001).
The antagonist naloxone precipitates withdrawal in mice chronically administered morphine. After 21 days of daily morphine treatment, naloxone (1 mg/kg, s.c.) precipitated withdrawal in wild-type mice, quantified by jumping (Fig. 1d) . Despite a diminished level of tolerance, the E11 KO mice jumped significantly more frequently than WT mice (Student's t test (t 22 = 2.11, p = 0.047) *p < 0.05, **p < 0.01), suggesting a possible increased level of physical dependence and a dissociation of tolerance and physical dependence mechanisms. Together, the loss of E11-associated variants enhanced physical dependence and decreased tolerance.
Respiratory depression
Opioid-induced respiratory depression is a potentially lethal side effect of opioid therapy. In both wild-type and E11 KO mice, morphine produced similar drops in respiratory rate 30 min after morphine administration (Fig. 2a) . Nonlinear regression analysis revealed similar ED 50 values (95% confidence limits) in the wild-type (0.9 mg/kg (0.25, 3.4)) and E11 KO mice (2.5 mg/kg (1.8, 3.4)). Time-action curves with the different morphine doses confirmed the similar responses over the full 50 min of observation (Supplemental Fig. 3 ). Thus, respiratory depression was independent of 6TM Oprm1 variants.
Conditioned place preference
To determine the role of 6TM variants in morphine reward, wild-type and E11 KO mice were tested in a three-chamber conditioned place preference paradigm (Fig. 2b) . In this study, both genotypes demonstrated equivalent preference for morphine-paired contexts, implying that 6TM variants are not involved with morphine reward behavior. E11 KO animals (n = 10) demonstrated similar morphine CPP as WT controls (n = 10; two-way ANOVA, main effect of day (pre-and postconditioning) F 1,36 = 31.55, p = 0.0002, but not of genotype (WT, mutant) F 1,36 = 0.28, p = 0.7048). Both WT and E11 KO mice acquired a similar place preference to morphine (10 mg/ kg i.p.) as demonstrated by a significant increase in time spent in the morphine-paired chamber on post-conditioning versus pre-conditioning test day (Bonferroni post hoc, *p < 0.05).
Locomotor activity
Morphine (10 mg/kg, s.c.) produced a robust increase in locomotor activity in wild-type mice compared to saline controls which persisted for more than 60 min (Fig. 2c) . In contrast, E11 KO mice failed to show a significant increase in locomotor activity following morphine either in time-action or cumulative distance measures. A repeated-measures ANOVA (F 87,754 = 6.32, p < 0.0001) with Bonferroni multiple comparisons tests indicated that morphine in WT animals was significantly different from saline-treated WTand E11 KO-treated morphine at all time points following 5 min after injection. E11 KO morphine animals did not differ from E11 KO saline animals at any time point except 20 min post-injection (p < 0.01).
Integrating the time-action curves confirmed these differences (Fig. 2d) . A one-way ANOVA (F 3,26 = 29.15, p < 0.0001) with Bonferroni post hoc comparisons test indicated that the WT response to morphine differed significantly from the WT response to saline. The E11 KO response to morphine did not differ significantly from the E11 KO response to saline.
Hyperalgesia
Opioid-induced hyperalgesia is defined by an enhanced sensitivity to a painful stimulus following opioid exposure (see reviews Oladosu et al. 2015b; Roeckel et al. 2016) . To assess hyperalgesia, we treated mice with a high dose of morphine (10 mg/kg, s.c.) and assessed them in the warm water tail immersion assay, as previously reported (Elhabazi et al. 2014) . First, we confirmed morphine analgesia in this assay. Wild-type mice and E11 KO mice both displayed maximal analgesia 30 min following morphine (10 mg/kg, s.c.) administration (Supplemental Fig. 4 ) that persisted over the course of morphine dosing.
Latencies were assessed prior to any drug administration (baseline) and 24 h after the morphine or saline injection, prior to the next morphine injection. This was repeated for another 3 days. The tail withdrawal latencies 24 h after morphine dosing were lower in wild-type mice after the first dose and each of the subsequent doses, indicating hyperalgesia (Fig. 3a) . In contrast, E11 KO mice failed to show a change in withdrawal latency during this 4-day period despite the potent analgesia seen 30 min after morphine dosing in both groups of mice (Figure Supplemental 4) . A repeated-measures ANOVA indicated that morphine significantly decreased baseline tail flick latencies in WT (F 4,148 = 14.75, p < 0.0001) but not E11 KO mice (F 4,148 = 0.7, p = 0.6). Thus, 6TM variants are important in the expression of morphine hyperalgesia but not analgesia.
To determine if the direct stimulation of a 6TM target also induced hyperalgesia, we examined IBNtxA. IBNtxA analgesia is independent of classical mu, delta, or kappa receptors, as indicated by its persistence in a Btriple knockout mouseP sychopharmacology (2017) 234:1891-1900 lacking these receptors (Majumdar et al. 2011) . Instead, IBNtxA analgesia is mediated through a 6TM-dependent 125 I-IBNtxA binding site in the brain unrelated to the classical opioid receptors. In the tail immersion assay, IBNtxA at a dose approximately fivefold higher than its ED 50 revealed near maximal analgesia 30 min after administration as anticipated (Supplemental Fig. 4) , which did not decline with repeated testing over the duration of the study. The IBNtxA response was markedly decreased in the E11 KO mice, dropping to nearly baseline levels. The slight, but significant, increased latency remaining in the E11 KO mice presumably reflected interactions with an alternative non-E11-dependent target.
Despite its analgesic activity, this dose of IBNtxA (1.6 mg/ kg, s.c.) failed to display hyperalgesia in either wild-type of E11 KO animals. Tail withdrawal latencies 24 h after IBNtxA dosing in either group were unchanged from baseline values (Fig. 3c) . A repeated-measures ANOVA indicated the absence of a significant change in latencies in WT or E11 KO mice. A prior study reported IBNtxA hyperalgesia utilizing an escalating paradigm with IBNtxA doses higher than our own (Samoshkin et al. 2015) . Utilizing their dosing regimen, we observed similar decreased tail withdrawal latencies (Supplemental Fig. 5 ). However, these decreases seen with the higher IBNtxA doses represented Boff target^effects unrelated to E11 sites since similar effects were present in both wild-type and E11 KO mice.
Discussion
Morphine produces a range of activities, including, paradoxically, hyperalgesia. Early studies carried out prior to the cloning of the mu receptors revealed that many morphine actions could be classified as naloxonazine-sensitive (also termed mu 1 ) or insensitive (mu 2 ), leading to the concept of mu opioid receptor subtypes (Wolozin and Pasternak 1981) . Systemic and supraspinal morphine analgesia are naloxonazinesensitive while respiratory depression, inhibition of gastrointestinal transit, and many signs of physical dependence are not (Hahn et al. 1982; Heyman et al. 1988; Ling et al. 1984; Ling et al. 1985; Pasternak 2001; Pasternak and Pan 2013; Paul and Pasternak 1988; Spiegel et al. 1982) . The cloning of dozens of Oprm1 splice variants confirmed the concept of multiple mu receptors (see review , although their correlation with naloxonazine sensitivity remains unclear. Both antisense (Rossi et al. 1994; Uhl et al. 1994) and knockout approaches established the importance of the 7TM variants in morphine analgesia (Charbogne et al. 2014; Corder et al. 2017; Kitanaka et al. 1998; Loh et al. 1998; Matthes et al. 1996; Schuller et al. 1999; Sora et al. 2001; Sora et al. 1997; Tian et al. 1997 ). However, not all Oprm1 gene products are needed for morphine analgesia, as illustrated by the maintenance of morphine analgesia in the E11 KO mice lacking 6TM variants using both the tail flick and the tail immersion assays. Furthermore, morphine analgesia in the E11 KO mice was equally sensitive to naloxonazine as wild-type animals, indicating that this naloxonazinesensitive action does not involve 6TM mechanisms.
The role of 6TM variants in other morphine actions was mixed. Both conditioned place preference and respiratory depression depended upon 7TM mechanisms while locomotor activity and tolerance utilized 6TM ones (Table S1 ). The persistence of respiratory depression in the E11 KO mice is interesting since this morphine action is insensitive to naloxonazine (Ling et al. 1985; Ling et al. 1983; Pasternak and Pan 2013) while morphine CPP is naloxonazine-sensitive (Bardo et al. 2003; Piepponen et al. 1997) , implying that 7TM variants elicit both naloxonazine-sensitive and insensitive morphine actions. Similarly, morphine-conditioned place preference was maintained in the E11 KO mice, indicating the lack of 6TM involvement. The lack of association of 6TM variants with respiratory depression and reward fits with earlier work examining IBNtxA. IBNtxA produces a potent analgesia dependent upon only 6TM Oprm1 receptors and lacks respiratory depression or reward activity in the place preference assay Majumdar et al. 2011) . Thus, 6TM targets may offer an opportunity to generate potent analgesics lacking these side effects. The loss of morphineinduced hyperlocomotion in the E11 KO mice is interesting since exon 11 immunoreactivity is present in a number of motor regions (i.e., striatum, globus pallidus, and substantia nigra) (Abbadie et al. 2004) .
Morphine hyperalgesia can be traced back to studies by Crain and colleagues reporting excitatory actions (Crain and Shen 1990) , followed by a report suggesting a mu 3 receptor mechanism (Stefano et al. 1995) . The mu 3 receptor corresponds to a truncated 6TM mu receptor variant (Cadet et al. 2003 ) that shares the same predicted protein structure as Fig. 3 Role of exon 11 variants in morphine-induced hyperalgesia. a Groups of WT and b E11 KO mice (n = 10-20 per group) were tested in the warm water tail immersion assay three times to obtain a baseline value (labeled Baseline) after which they received saline (closed triangles) or morphine (open circles; 10 mg/kg, s.c.) and latencies again determined 24 h later. This was repeated two more times. Data are reported as average latency. Bonferroni postcomparisons test, four asterisks indicate p < 0.0001. c Groups of WT (closed triangles) and E11 KO mice (open circles; n = 10-20 per group) were tested in the warm water tail immersion assay three times to obtain a baseline. Then, mice were given saline or IBNtxA (1.6 mg/kg, s.c.) and tested 24 h later. Following testing, the drug was administered again, and tail withdrawal latency was assessed again 24 h later and this was repeated two more times. Data are reported as mean ± s.e.m.
MOR-1K and MOR-1L Shabalina et al. 2009; Xu et al. 2009 ). More recent work suggested that MOR-1K stimulation leads to excitatory effects mediated through G s (Gris et al. 2010; Oladosu et al. 2015a) . While MOR-1K remains a candidate variant for hyperalgesia, our current results cannot distinguish between MOR-1K and the four other 6TM variants produced by the exon 11 promoter in mice. Three of them translate exon 11, skip exon 1, and then read through exons 2 and 3 followed by the alternatively spliced downstream exons. MOR-1K and MOR-1L and mu 3 , on the other hand, do not translate exon 11, generating identical proteins whose sequence is defined by translation of exons 2, 3, and 4. Our studies cannot distinguish among them since all 6TM variants are eliminated in the E11 KO mouse.
Different sets of Oprm1 variants mediate morphine analgesia and hyperalgesia. While 7TM receptors are essential for morphine analgesia, morphine hyperalgesia requires only 6TM mechanisms. Using Btriple knockout mice^derived by crossing their exon 1 MOR-1 KO (Schuller et al. 1999 ) with delta and kappa receptor knockout mice, Pintar and Kest observed the loss of morphine analgesia but the retention of morphine-induced hyperalgesia (Juni et al. 2007 ). These animals lack all traditional mu, delta, and kappa opioid receptors, expressing only the 6TM Oprm1 variants. Thus, the Juni et al. paper shows the persistence of morphine hyperalgesia in the absence of analgesia while our study shows analgesia in the absence of hyperalgesia. The relationship of morphine hyperalgesia to tolerance remains uncertain, but it is interesting that 6TM variants are involved with both. A contribution of 6TM mechanisms to tolerance is consistent with the upregulation of 6TM mRNA transcripts following long-term morphine exposure . Morphine administered twice daily for 6 weeks increased mMOR-1G mRNA expression by nearly 40-fold in the brainstem and 90-fold in the hypothalamus while mMOR-1K mRNA increased over 40-fold in the hippocampus and 15-fold in the brainstem and mMOR-1M increased almost 50-fold in the brainstem.
While our findings expand our understanding of the role of 6TM variants, they also raise questions. Clearly, E11 mechanisms play a role in morphine hyperalgesia, but it is unlikely that these involve the E11-dependent IBNtxA binding site identified in the brain (Majumdar et al. 2011 ). Morphine concentrations in the brain associated with analgesia (~0.2 μM) (Patrick et al. 1975 ) are far lower than its binding affinity for the IBNtxA 6TM binding site in the brain (K i > 1 μM), and the direct activation of the E11 IBNtxA target failed to produce hyperalgesia. Thus, morphine hyperalgesia involves an alternative 6TM-associated target. 6TM variants participate in a broad range of actions mediated by receptor systems other than mu, including delta and kappa opioid and α 2 adrenergic analgesia (Marrone et al. 2016) , while MOR-1K interacts with β 2 adrenergic receptors, a possible mechanism for hyperalgesia (Samoshkin et al. 2015) . Thus, the 6TM variants may play a more extensive role than originally thought and the current findings provide further evidence for the diverse pharmacology of different mu opioid receptor splice variants.
